At a glance
- Originator Takeda
- Class Anti-ischaemics; Neuroprotectants
- Mechanism of Action Antioxidants; Dopamine release inhibitors; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 11 Oct 2000 Discontinued-II for Stroke in Japan (Unknown route)
- 11 Oct 2000 Discontinued-II for Stroke in USA (Unknown route)
- 07 Sep 2000 No-Development-Reported for Stroke in Japan (Unknown route)